Cargando…
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetim...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Association of Internal Medicine
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636547/ https://www.ncbi.nlm.nih.gov/pubmed/37866817 http://dx.doi.org/10.3904/kjim.2023.243 |